JP2020502132A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020502132A5 JP2020502132A5 JP2019531806A JP2019531806A JP2020502132A5 JP 2020502132 A5 JP2020502132 A5 JP 2020502132A5 JP 2019531806 A JP2019531806 A JP 2019531806A JP 2019531806 A JP2019531806 A JP 2019531806A JP 2020502132 A5 JP2020502132 A5 JP 2020502132A5
- Authority
- JP
- Japan
- Prior art keywords
- skin
- composition according
- plasminogen
- drug composition
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 10
- 229940079593 drugs Drugs 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 108010051456 Plasminogen Proteins 0.000 claims 6
- 102000013566 Plasminogen Human genes 0.000 claims 6
- 210000003491 Skin Anatomy 0.000 claims 6
- 206010050207 Skin fibrosis Diseases 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 3
- 230000001363 autoimmune Effects 0.000 claims 2
- 230000001684 chronic Effects 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 206010000496 Acne Diseases 0.000 claims 1
- 206010003816 Autoimmune disease Diseases 0.000 claims 1
- 102000008186 Collagen Human genes 0.000 claims 1
- 108010035532 Collagen Proteins 0.000 claims 1
- 208000005679 Eczema Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010022114 Injury Diseases 0.000 claims 1
- 208000002260 Keloid Diseases 0.000 claims 1
- 210000001117 Keloid Anatomy 0.000 claims 1
- 206010023330 Keloid scar Diseases 0.000 claims 1
- 102000001938 Plasminogen Activators Human genes 0.000 claims 1
- 108010001014 Plasminogen Activators Proteins 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000006641 Skin Disease Diseases 0.000 claims 1
- 206010040882 Skin lesion Diseases 0.000 claims 1
- 230000000172 allergic Effects 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 claims 1
- 229960005188 collagen Drugs 0.000 claims 1
- 229920001436 collagen Polymers 0.000 claims 1
- 239000002537 cosmetic Substances 0.000 claims 1
- 201000004624 dermatitis Diseases 0.000 claims 1
- 231100001003 eczema Toxicity 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 108010087750 lysyl-plasminogen Proteins 0.000 claims 1
- 108010049112 miniplasminogen Proteins 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 201000004681 psoriasis Diseases 0.000 claims 1
- 230000037380 skin damage Effects 0.000 claims 1
- 231100000444 skin lesion Toxicity 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
Claims (14)
- 有効量のプラスミノーゲンを含む、被験者の皮膚疾患による皮膚コラーゲンの沈着または繊維化を予防または治療するための薬物組成物。
- 前記疾患は、皮膚の慢性自己免疫性疾患である、請求項１に記載の薬物組成物。
- 前記疾患は、強皮症、全身性エリテマトーデス、ざ瘡、湿疹、および、乾癬を含む、請求項２に記載の薬物組成物。
- 前記疾患は皮膚の慢性炎症である、請求項１に記載の薬物組成物。
- 皮膚線維化が、被験者の自己免疫反応により引き起こされる、請求項１に記載の薬物組成物。
- 皮膚線維化が、被験者の皮膚損傷により引き起こされる、請求項１に記載の薬物組成物。
- 前記皮膚損傷は、皮膚外傷、手術切創、または化学物質損傷である、請求項６に記載の薬物組成物。
- 皮膚線維化が、アレルギー性皮膚繊維化または被検者の自己免疫反応により引き起こされる皮膚線維化である、請求項１に記載の薬物組成物。
- 前記被験者はケロイド体質である、請求項８に記載の薬物組成物。
- 前記薬物組成物を皮膚局所に投与する、請求項１〜９のいずれか１項に記載の薬物組成物。
- 前記薬物組成物は１種以上の薬物、スキンケア用品および／または化粧品と組み合わせて投与する、請求項１〜１０のいずれか１項に記載の薬物組成物。
- 前記プラスミノーゲンは配列２と少なくとも７５％、８０％、８５％、９０％、９５％、９６％、９７％、９８％または９９％の配列同一性を有し、且つ依然プラスミノーゲン活性を有するものである、請求項１〜１１のいずれか１項に記載の薬物組成物。
- 前記プラスミノーゲンは配列１４に示されるプラスミノーゲン活性フラグメントを含有し、且つ依然プラスミノーゲン活性を有するタンパク質である、請求項１〜１２のいずれか１項に記載の薬物組成物。
- 前記プラスミノーゲンは、Ｇｌｕ−プラスミノーゲン、Ｌｙｓ−プラスミノーゲン、ミニプラスミノーゲン、マイクロプラスミノーゲン、δ−プラスミノーゲンまたはそれらのプラスミノーゲン活性を保持した変異体である、請求項１〜１２のいずれか１項に記載の薬物組成物。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2016/110174 | 2016-12-15 | ||
| CN2016110174 | 2016-12-15 | ||
| PCT/CN2017/089054 WO2018107694A1 (zh) | 2016-12-15 | 2017-06-19 | 一种预防和治疗皮肤纤维化的方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020502132A JP2020502132A (ja) | 2020-01-23 |
| JP2020502132A5 true JP2020502132A5 (ja) | 2020-07-30 |
Family
ID=62557850
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019531811A Active JP7313058B2 (ja) | 2016-12-15 | 2017-06-19 | 組織器官の繊維化を予防及び治療するための方法 |
| JP2019531805A Active JP7213552B2 (ja) | 2016-12-15 | 2017-06-19 | 肝の繊維化を予防及び治療するための方法 |
| JP2019531808A Active JP7213553B2 (ja) | 2016-12-15 | 2017-06-19 | 肺の繊維化を予防及び治療するための方法 |
| JP2019531806A Pending JP2020502132A (ja) | 2016-12-15 | 2017-06-19 | 皮膚の繊維化を予防及び治療するための方法 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019531811A Active JP7313058B2 (ja) | 2016-12-15 | 2017-06-19 | 組織器官の繊維化を予防及び治療するための方法 |
| JP2019531805A Active JP7213552B2 (ja) | 2016-12-15 | 2017-06-19 | 肝の繊維化を予防及び治療するための方法 |
| JP2019531808A Active JP7213553B2 (ja) | 2016-12-15 | 2017-06-19 | 肺の繊維化を予防及び治療するための方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US11071772B2 (ja) |
| EP (4) | EP3556395A4 (ja) |
| JP (4) | JP7313058B2 (ja) |
| CN (4) | CN110139668A (ja) |
| CA (4) | CA3046666A1 (ja) |
| TW (6) | TWI734798B (ja) |
| WO (5) | WO2018107698A1 (ja) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7313058B2 (ja) | 2016-12-15 | 2023-07-24 | タレンゲン インターナショナル リミテッド | 組織器官の繊維化を予防及び治療するための方法 |
| CN111344004A (zh) | 2017-06-19 | 2020-06-26 | 泰伦基国际有限公司 | 一种调控glp-1/glp-1r 的方法和药物 |
| TW201904990A (zh) * | 2017-06-23 | 2019-02-01 | 美商波麥堤克生物治療股份有限公司 | 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療 |
| CA3167593A1 (en) * | 2020-02-11 | 2021-08-19 | Jinan Li | Method and drug for treating viral pneumonia |
| WO2023008283A1 (ja) | 2021-07-30 | 2023-02-02 | 花王株式会社 | パンツ型吸収性物品 |
| CN114984032B (zh) * | 2022-06-27 | 2023-07-07 | 四川大学 | Dna四面体框架核酸-绿原酸复合物及其在制备治疗肝纤维化的药物中的用途 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4645668A (en) * | 1983-08-04 | 1987-02-24 | Biospecifics, Nv | Method for the prevention and treatment of scars with enzymes |
| GB8721951D0 (en) | 1987-09-18 | 1987-10-28 | Thrombosis Research Trust | Organic compounds |
| EP1516628B1 (en) | 1995-07-27 | 2013-08-21 | Genentech, Inc. | Stable isotonic lyophilized protein formulation |
| EP0910571B1 (en) * | 1996-05-03 | 2005-07-20 | Abbott Laboratories | Novel antiangiogenic peptides, polynucleotides encoding same and methods for inhibiting angiogenesis |
| EP1001985A1 (en) | 1997-06-26 | 2000-05-24 | Karolinska Innovations AB | Kringle domains 1-5 of plasminogen, capable of modulating angiogenesis in vivo |
| AU5571799A (en) | 1998-08-20 | 2000-03-14 | University Of Vermont And State Agricultural College, The | Angiogenesis inhibitors and uses thereof |
| US7763580B2 (en) | 1999-01-05 | 2010-07-27 | University Of Utah Research Foundation | Methods for treating conditions associated with the accumulation of excess extracellular matrix |
| AU2002239414A1 (en) | 2000-11-02 | 2002-05-27 | Bristol-Myers Squibb Company | Modified plasminogen related peptide fragments and their use as angiogenesis inhibitors |
| MXPA00011713A (es) | 2000-11-28 | 2002-05-31 | Tgt Lab S A De C V | Vectores recombinantes virales y no virales conteniendo el gen humano del activador de plasminogeno derivado de urocinasa y su utilidad en el tratamiento de diversos tipos de fibrosis hepatica, renal, pulmonar, pancreatica, cardiaca y cicatrices hipe |
| US7067492B2 (en) | 2001-09-06 | 2006-06-27 | Omnio Ab | Method of promoting healing of a tympanic membrane perforation |
| CN1768138A (zh) | 2002-02-06 | 2006-05-03 | N-酶生物技术有限公司 | 在微生物中生产重组蛋白质的方法 |
| DE10390418D2 (de) * | 2002-02-06 | 2005-01-13 | N Zyme Biotec Gmbh | Verfahren zur Herstellung von rekombinanten Proteinen in Mikroorganismen |
| US20040043026A1 (en) | 2002-05-13 | 2004-03-04 | Tai-Lan Tuan | Treatment and prevention of abnormal scar formation in keloids and other cutaneous or internal wounds or lesions |
| US7348351B2 (en) | 2002-12-10 | 2008-03-25 | Wyeth | Substituted 3-alkyl and 3-arylalkyl 1H-indol-1yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) |
| US20050250694A1 (en) | 2003-10-10 | 2005-11-10 | Ma Jian-Xing | Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same |
| CA2577782A1 (en) | 2004-08-23 | 2006-03-02 | Wyeth | Pyrrolo-naphthyl acids as pai-1 inhibitors |
| CN101563100B (zh) * | 2006-08-28 | 2013-08-07 | 李季男 | 用于预防和治疗牙周病、改善牙周创伤愈合以及促进口腔健康的新药物靶标 |
| US20100080773A1 (en) | 2008-09-26 | 2010-04-01 | Sdg, Inc. | Orally Bioavailable Lipid-Based Constructs |
| PT2220221E (pt) | 2007-11-29 | 2015-04-16 | Grifols Therapeutics Inc | Plasmina modificada de forma recombinante |
| US8697840B2 (en) * | 2008-03-05 | 2014-04-15 | Board Of Regents, The University Of Texas System | Peptide inhibition of lung epithelial apoptosis and pulmonary fibrosis |
| CN102482338B (zh) | 2009-07-10 | 2016-09-28 | 斯路姆基因公司 | 纤溶酶原和纤溶酶的变体 |
| CN101628113B (zh) | 2009-08-18 | 2012-01-04 | 南京农业大学 | 蚯蚓纤溶酶抗肝纤维化的应用 |
| CA2779905A1 (en) | 2009-11-07 | 2011-05-12 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| WO2011139974A2 (en) * | 2010-05-03 | 2011-11-10 | Abbott Laboratories | Anti-pai-1 antibodies and methods of use thereof |
| CN102121023B (zh) | 2010-12-22 | 2012-07-04 | 中山大学 | 突变型人纤溶酶原kringle5及其制备方法及应用 |
| KR20140015289A (ko) * | 2011-01-05 | 2014-02-06 | 쓰롬보제닉스 엔.브이. | 플라스미노겐 및 플라스민 변이체 |
| CN102154253A (zh) | 2011-01-06 | 2011-08-17 | 郑州大学 | 具有抑制血小板凝集功能的微小纤溶酶原突变体及其制备方法和用途 |
| US9655973B2 (en) | 2012-03-09 | 2017-05-23 | Vascular Biosciences | Orally active, cell-penetrating homing peptide and methods of using same |
| KR101467109B1 (ko) | 2013-07-10 | 2014-12-01 | 영남대학교 산학협력단 | Ｂｉｘ02189 화합물을 유효성분으로 포함하는 폐섬유증 예방 또는 치료용 조성물 |
| BR112016002753A2 (pt) * | 2013-08-13 | 2017-11-21 | Sanofi Sa | anticorpos contra o inibidor-1 de ativador de plasminogênio (pai-1) e usos dos mesmos |
| TW201734054A (zh) | 2013-08-13 | 2017-10-01 | 賽諾菲公司 | 胞漿素原活化素抑制劑-１（ｐａｉ-１）之抗體及其用途 |
| CN104371019B (zh) | 2013-08-13 | 2019-09-10 | 鸿运华宁（杭州）生物医药有限公司 | 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质 |
| WO2015026494A2 (en) * | 2013-08-20 | 2015-02-26 | Trustees Of Dartmouth College | Methods for treating tissue fibrosis |
| WO2015125904A1 (ja) | 2014-02-21 | 2015-08-27 | アステラス製薬株式会社 | 新規抗ヒトｐａｉ－１抗体 |
| AU2015367185B2 (en) | 2014-12-19 | 2021-05-27 | Prometic Bio Therapeutics, Inc. | Pharmaceutical composition comprising plasminogen and uses thereof |
| TWI801331B (zh) | 2015-11-03 | 2023-05-11 | 美商波麥堤克生物治療股份有限公司 | 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法 |
| CN106890318A (zh) | 2015-12-18 | 2017-06-27 | 深圳瑞健生命科学研究院有限公司 | 一种预防和治疗糖尿病性心脏病的新方法 |
| CN106890320A (zh) | 2015-12-18 | 2017-06-27 | 深圳瑞健生命科学研究院有限公司 | 一种用于预防或治疗急性及慢性血栓的方法 |
| CN108463236A (zh) | 2015-12-18 | 2018-08-28 | 泰伦基国际有限公司 | 一种预防或治疗放射性和化学性损伤的方法 |
| US11400142B2 (en) | 2015-12-18 | 2022-08-02 | Talengen International Limited | Treatment of diabetic nerve injury comprising administering plasminogen |
| EP3395359B1 (en) | 2015-12-18 | 2023-11-01 | Talengen International Limited | Plasminogen for use in preventing or treating acute thrombosis and chronic thrombosis |
| DK3391902T3 (da) | 2015-12-18 | 2023-11-20 | Talengen Int Ltd | Plasminogen til anvendelse i behandlingen af diabetisk angiokardiopati |
| CN106890324A (zh) | 2015-12-18 | 2017-06-27 | 深圳瑞健生命科学研究院有限公司 | 一种预防和治疗糖尿病肾病的方法 |
| CN110114079A (zh) | 2016-12-15 | 2019-08-09 | 泰伦基国际有限公司 | 一种预防和治疗肥胖症的方法和药物 |
| WO2018107687A1 (zh) * | 2016-12-15 | 2018-06-21 | 深圳瑞健生命科学研究院有限公司 | 一种预防和治疗高脂血症的方法 |
| CN110366427A (zh) * | 2016-12-15 | 2019-10-22 | 泰伦基国际有限公司 | 一种预防和治疗病理性肾组织损伤的方法 |
| CA3047175A1 (en) * | 2016-12-15 | 2018-06-21 | Talengen International Limited | Method for mitigating heart disease |
| EP3556384B1 (en) | 2016-12-15 | 2024-04-10 | Talengen International Limited | Plasminogen for use in treating diabetes |
| JP7313058B2 (ja) | 2016-12-15 | 2023-07-24 | タレンゲン インターナショナル リミテッド | 組織器官の繊維化を予防及び治療するための方法 |
| CN111344004A (zh) * | 2017-06-19 | 2020-06-26 | 泰伦基国际有限公司 | 一种调控glp-1/glp-1r 的方法和药物 |
-
2017
- 2017-06-19 JP JP2019531811A patent/JP7313058B2/ja active Active
- 2017-06-19 CA CA3046666A patent/CA3046666A1/en active Pending
- 2017-06-19 CA CA3046669A patent/CA3046669A1/en not_active Abandoned
- 2017-06-19 EP EP17882248.2A patent/EP3556395A4/en active Pending
- 2017-06-19 TW TW106120453A patent/TWI734798B/zh active
- 2017-06-19 US US16/470,186 patent/US11071772B2/en active Active
- 2017-06-19 CN CN201780078166.7A patent/CN110139668A/zh active Pending
- 2017-06-19 US US16/470,172 patent/US11219669B2/en active Active
- 2017-06-19 TW TW110101502A patent/TW202123955A/zh unknown
- 2017-06-19 TW TW106120456A patent/TWI670075B/zh active
- 2017-06-19 CA CA3047174A patent/CA3047174A1/en not_active Abandoned
- 2017-06-19 WO PCT/CN2017/089058 patent/WO2018107698A1/zh unknown
- 2017-06-19 EP EP17880059.5A patent/EP3556380A4/en active Pending
- 2017-06-19 CN CN201780078132.8A patent/CN110121358A/zh active Pending
- 2017-06-19 JP JP2019531805A patent/JP7213552B2/ja active Active
- 2017-06-19 TW TW106120457A patent/TW201822790A/zh unknown
- 2017-06-19 WO PCT/CN2017/089056 patent/WO2018107696A1/zh unknown
- 2017-06-19 US US16/470,179 patent/US11154595B2/en active Active
- 2017-06-19 CA CA3046671A patent/CA3046671C/en active Active
- 2017-06-19 CN CN201780078123.9A patent/CN110114080A/zh active Pending
- 2017-06-19 WO PCT/CN2017/089054 patent/WO2018107694A1/zh unknown
- 2017-06-19 EP EP17881523.9A patent/EP3556389A4/en active Pending
- 2017-06-19 TW TW106120454A patent/TWI752044B/zh active
- 2017-06-19 JP JP2019531808A patent/JP7213553B2/ja active Active
- 2017-06-19 WO PCT/CN2017/089057 patent/WO2018107697A1/zh unknown
- 2017-06-19 WO PCT/CN2017/089053 patent/WO2018107693A1/zh active Application Filing
- 2017-06-19 CN CN201780078169.0A patent/CN110191718A/zh active Pending
- 2017-06-19 JP JP2019531806A patent/JP2020502132A/ja active Pending
- 2017-06-19 EP EP17880398.7A patent/EP3556382A4/en active Pending
- 2017-06-19 US US16/470,162 patent/US20190314466A1/en not_active Abandoned
- 2017-06-19 TW TW106120449A patent/TWI657823B/zh active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020502132A5 (ja) | ||
| CL2019002960A1 (es) | Péptido con actividad anti-obesidad y anti-diabetes y uso del mismo. (divisional solicitud 201702718) | |
| Laureano et al. | Facial bacterial infections: folliculitis | |
| JP2016516808A5 (ja) | ||
| BR112014019431A8 (pt) | Método compartimentalizado de distribuição de ácido nucleico e composições e usos desses | |
| BR112012018500A2 (pt) | alguns inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de uso destas | |
| BR112014004845A2 (pt) | pelo menos uma entidade química; pelo menos um composto; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada | |
| JP2017537936A5 (ja) | ||
| BR112021006167A8 (pt) | Partículas de rna compreendendo polisarcosina | |
| WO2015085143A3 (en) | Therapeutic agents for skin diseases and conditions | |
| JP2017518370A5 (ja) | ||
| Feldman et al. | Current drug therapies for rosacea: a chronic vascular and inflammatory skin disease | |
| Gilbert et al. | Efficacy of botulinum neurotoxin type A for treating recalcitrant plaque psoriasis | |
| Sin et al. | SIRT1-dependent myoprotective effects of resveratrol on muscle injury induced by compression | |
| Zakeri et al. | Topical calcipotriol therapy in nail psoriasis: a study of 24 cases | |
| Kim et al. | Proactive treatment of adult facial seborrhoeic dermatitis with 0.1% tacrolimus ointment: randomized, double-blind, vehicle-controlled, multi-centre trial | |
| MX2016016400A (es) | Formulaciones de oximetazolina estabilizadas y sus usos. | |
| Lee et al. | Blastomycosis-like pyoderma with good response to acitretin | |
| JP2013520447A5 (ja) | ||
| WO2016191458A3 (en) | Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment | |
| Berman et al. | Evaluating the tolerability and efficacy of etanercept compared to triamcinolone acetonide for the intralesional treatment of keloids. | |
| DK2004235T3 (da) | Sammensætning til kosmetisk eller farmaceutisk-dermatologisk anvendelse | |
| CL2020001791A1 (es) | Composiciones farmacéuticas para la piel tópicas que contienen cerdulatinib y usos de estas. | |
| Saco et al. | Severe radiation dermatitis associated with concomitant vemurafenib therapy in a patient with metastatic melanoma | |
| MX2018013474A (es) | Acidos carboxilicos para aplicacion en la primera infancia. |